Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Feb 21:10:49.
doi: 10.1186/1471-2407-10-49.

Hemorrhage of brain metastasis from non-small cell lung cancer post gefitinib therapy: two case reports and review of the literature

Dan-Fang Yan  1 , Sen-Xiang Yan, Jing-Song Yang, Yi-Xiang J Wang, Xiao-Li Sun, Xin-Biao Liao, Jun-Qing Liu
Affiliations
Review

Hemorrhage of brain metastasis from non-small cell lung cancer post gefitinib therapy: two case reports and review of the literature

Dan-Fang Yan et al. BMC Cancer. .

Abstract

Background: Gefitinib is one of the small molecule inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR TKIs). Clinical trials have demonstrated it is effective for treatment of a subset of patients with advanced non-small cell lung cancer (NSCLC). Gefitinib has been generally considered to be a relatively safe agent. Besides a small proportion of fatal interstitial pneumonia, the common adverse drug reactions of gefitinib include diarrhea and skin rash, which are generally mild and reversible. Herein, we report the first two cases of brain metastasis hemorrhage that might be involved with the use of gefitinib.

Case presentation: Two patients with brain metastasis from NSCLC developed brain hemorrhage after gefitinib therapy. The hemorrhage in one case occurred one month after gefitinib combined with whole brain radiation therapy (WBRT), and in the another case hemorrhage developed slowly within brain metastases eight months post gefitinib monotherapy for diffuse pulmonary metastasis from a lung cancer undergone surgical removal previously.

Conclusion: We speculate brain hemorrhage could be one of the adverse drug reactions of gefitinib treatment for NSCLC and suggest clinicians be aware of this possible rare entity. More data are needed to confirm our findings, especially when gefitinib is used in the settings of brain metastases from NSCLC or other origins.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Case 1. A: Prior to gefitinib therapy, chest CT scan shows a primary lesion (arrow) in the upper lobe of right lung and multiple pulmonary metastatic nodules (arrowheads) in both lungs. B: One month later with gefitinib therapy, chest CT scan shows significant shrinkage of the primary lesion (arrow) as well as marked absorption of metastatic nodules.
Figure 2
Figure 2
Case 1. A: Contrast-enhanced T1-weighted brain MRI shows multiple metastatic lesions, with the largest one (arrow) in the left occipital lobe. B: One month later with gefitinib therapy together with two weeks' WBRT, T1-weighted MRI demonstrates a subacute hematoma (arrow) in the metastatic lesion.
Figure 3
Figure 3
Case 2. A: Chest CT scans shows pulmonary metastatic dissemination (arrows) from a previously operated NSCLC in the right lung. A patchy shadow (arrowhead) representing radiation-induced fibrosis is also observed. B: About 2 month later with gefitinib therapy, chest CT scan shows significant absorption of the metastatic lesions.
Figure 4
Figure 4
Case 2. A: T1-weighted brain MRI shows a metastatic lesion of heterogeneous signal intensities in the left thalamus (arrow). Components of hyper-signal intensities represent subacute hemorrhage. B: This lesion is also of heterogeneous signal intensities on T2-weighted images, with components of hypointense hemosiderins representing chronic hemorrhage (arrow). C: Contrast-enhanced MRI shows inhomogeneous enhancement of the lesion (arrow).
See this image and copyright information in PMC

References

    1. Raymond E, Faivre S, Armand JP. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs. 2000;60:15–23. doi: 10.2165/00003495-200060001-00002. - DOI - PubMed
    1. Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, Thongprasert S, Tan EH, Pemberton K, Archer V, Carroll K. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) Lancet. 2005;366:1527–37. doi: 10.1016/S0140-6736(05)67625-8. - DOI - PubMed
    1. Niho S, Ichinose Y, Tamura T, Yamamoto N, Tsuboi M, Nakagawa K, Shinkai T, Jiang H, Nishiwaki Y, Fukuoka M. Results of a randomized phase iii study to compare the overall survival of gefitinib (IRESSA) versus docetaxel in Japanese patients with non-small-cell lung cancer who failed one or two chemotherapy regimens. Proc Am Soc Clin Oncol. 2007;25(18S) [abstr LBA7509]
    1. Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, Li LY, Watkins CL, Sellers MV, Lowe ES, Sun Y, Liao ML, Osterlind K, Reck M, Armour AA, Shepherd FA, Lippman SM, Douillard JY. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet. 2008;372:1809–18. doi: 10.1016/S0140-6736(08)61758-4. - DOI - PubMed
    1. Park J, Park BB, Kim JY, Lee SH, Lee SI, Kim HY, Kim JH, Park SH, Lee KE, Park JO, Kim K, Jung CW, Park YS, Im YH, Kang WK, Lee MH, Park K. Gefitinib (ZD1839) monotherapy as a salvage regimen for previously treated advanced non-small cell lung cancer. Clin Cancer Res. 2004;10:4383–8. doi: 10.1158/1078-0432.CCR-04-0189. - DOI - PubMed

MeSH terms